Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Stonebrook Private Inc.

Stonebrook Private Inc. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 488 shares of the medical research company’s stock after selling 34 shares during the quarter. Stonebrook Private Inc.’s holdings in Thermo Fisher Scientific were worth $254,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC increased its stake in shares of Thermo Fisher Scientific by 4.1% in the 4th quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company’s stock worth $367,000 after acquiring an additional 28 shares during the last quarter. Merit Financial Group LLC increased its stake in shares of Thermo Fisher Scientific by 54.4% in the 4th quarter. Merit Financial Group LLC now owns 9,851 shares of the medical research company’s stock worth $5,125,000 after acquiring an additional 3,470 shares during the last quarter. Sanibel Captiva Trust Company Inc. increased its stake in shares of Thermo Fisher Scientific by 5.4% in the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 1,935 shares of the medical research company’s stock worth $1,007,000 after acquiring an additional 99 shares during the last quarter. HB Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 2.0% in the 4th quarter. HB Wealth Management LLC now owns 13,027 shares of the medical research company’s stock worth $6,777,000 after acquiring an additional 256 shares during the last quarter. Finally, Smith Salley Wealth Management increased its position in shares of Thermo Fisher Scientific by 13.9% during the 4th quarter. Smith Salley Wealth Management now owns 48,671 shares of the medical research company’s stock worth $25,320,000 after purchasing an additional 5,954 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $412.15 on Monday. The stock has a 50-day simple moving average of $453.88 and a 200-day simple moving average of $509.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $155.58 billion, a PE ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the business posted $5.11 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date was Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TMO. Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 23rd. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Finally, Morgan Stanley raised their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $607.43.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,075 shares of company stock valued at $7,305,942. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.